Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

AstraZeneca’s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer – Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial

Fineline Cube Jul 24, 2026
Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Fineline Cube Jul 23, 2026
Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promising Results in Alopecia Phase III Trial

Fineline Cube Mar 21, 2025

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced positive topline results from the long-term safety Phase...

Company Drug

Junshi Biosciences Receives NMPA Approval for JS212 in Advanced Solid Tumors

Fineline Cube Mar 21, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced receiving clearance from the...

Company Drug

Hengrui’s Trastuzumab Rezetecan Nears 8th Breakthrough Therapy Designation

Fineline Cube Mar 21, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its trastuzumab rezetecan (SHR-A1811), an...

Company Drug

Fosun’s Henlius Receives FDA Orphan Drug Designation for HER2-Targeting HLX22

Fineline Cube Mar 20, 2025

On March 19, 2025, Fosun Pharmaceutical (SHA: 600196) announced that its subsidiary, Henlius, has received...

Company Deals

Paratek Pharmaceuticals to Acquire Optinose for $330 Million

Fineline Cube Mar 20, 2025

Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ: OPTN) announced a definitive merger agreement on March 19,...

Company Deals

Boji Medical’s Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong

Fineline Cube Mar 20, 2025

On March 20, 2025, Boji Medical Technology Co., Ltd (known as Boji Biomedicals) (SHE: 300404)...

Company Deals

Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery

Fineline Cube Mar 20, 2025

On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS:...

Company Drug

Joyo Pharma’s JYP0035 Receives Clinical Trial Approval for Breast Cancer Treatment

Fineline Cube Mar 20, 2025

On March 14, 2025, Joyo Pharma announced that its independently developed next-generation, highly selective Class...

Policy / Regulatory

CDE Announces 92nd Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Mar 20, 2025

China’s Center for Drug Evaluation (CDE) has released the 92nd batch of reference preparations for...

Company

HutchMed’s 2024 Financial Report Shows Dip in Revenue Amid Oncology Product Growth

Fineline Cube Mar 20, 2025

China-based HutchMed (NASDAQ: HCM, HKG: 0013) released its 2024 financial report, revealing a total revenue...

Company Deals

Servier and Black Diamond Therapeutics Ink Global Deal for BDTX-4933

Fineline Cube Mar 20, 2025

French pharmaceutical company Servier and US-based Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) announced a strategic...

Policy / Regulatory

NMPA Seeks Public Input on Drug Trial Data Protection Measures

Fineline Cube Mar 20, 2025

On March 19, 2025, China’s National Medical Products Administration (NMPA) released draft measures and procedures...

Company Medical Device

Telix Pharmaceuticals Gains Brazilian Approval for Prostate Cancer Diagnostic Agent TLX591-CDx

Fineline Cube Mar 19, 2025

Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) announced receiving clearance from the Brazilian Health Regulatory Agency...

Company Deals Hospital

Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services

Fineline Cube Mar 19, 2025

Shenzhen-based Distinct Healthcare Holdings Limited, a comprehensive medical service provider with integrated online and offline...

Company

Pfizer Restructures China Operations to Boost Growth and Innovation

Fineline Cube Mar 19, 2025

US-based pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced a significant leadership and organizational restructuring in...

Policy / Regulatory

CDE’s 2024 Annual Drug Review Report Shows Continued Growth in Regulatory Filings

Fineline Cube Mar 19, 2025

The Center for Drug Evaluation (CDE) released its 2024 annual drug review report, highlighting continued...

Company

Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production

Fineline Cube Mar 19, 2025

China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in...

Company Deals

GE Healthcare and NVIDIA Expand Partnership to Advance Autonomous X-ray and Ultrasound Technologies

Fineline Cube Mar 19, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced an...

Company Drug

Tonghua Dongbao Initiates Phase III Trial for Insulin Degludec, Liraglutide Combo in Type 2 Diabetes

Fineline Cube Mar 19, 2025

China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) has initiated a Phase III clinical study for its...

Company Deals

Formosa Pharmaceuticals Inks Licensing Pact with Cipla for APP13007 in 11 Countries

Fineline Cube Mar 19, 2025

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with India-headquartered Cipla Limited (BOM: 500087,...

Posts pagination

1 … 226 227 228 … 699

Recent updates

  • Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance
  • Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform
  • Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub
  • AstraZeneca’s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer – Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial
  • MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance

Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Company Drug

AstraZeneca’s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer – Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.